Physician profile
Benjamin N Blond
NPI 1760757017
$40,222.24
in general payments reported to CMS, 2019-2025
8 companies · $11K in 2025
The $11K reported for 2025 was more than what 91% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $222 · 2023: $15K · 2024: $14K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $8,111 · Food and Beverage: $2,876 · Travel and Lodging: $1,362 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,441.00 |
| Consulting Fee | $8,110.50 |
| Food and Beverage | $2,876.38 |
| Travel and Lodging | $1,362.09 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $21,897.12 | 2021-2025 | Nayzilam, Briviact, Fintepla |
| Neurelis, INC. | $16,195.47 | 2023-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $1,440.02 | 2023-2025 | Epidiolex |
| Sk Life Science, INC. | $343.97 | 2021-2025 | Xcopri |
| Neuropace, INC. | $161.37 | 2023-2025 | |
| Abbvie INC. | $114.74 | 2022-2023 | Ubrelvy, Qulipta |
| Depuy Synthes Sales INC. | $36.03 | 2021 | |
| Sumitomo Pharma America, INC. | $33.52 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Blond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.